What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology Professor of Medicine Division of Cardiovascular Medicine School of Medicine Oregon Health Sciences University (OHSU) Portland, OR